Low-grade adenosquamous carcinoma is a rare histologic subtype of breast carcinoma that has a variable mammographic and sonographic appearance, which overlaps with both benign and malignant neoplasms. Because of its lack of unique imaging features, a diagnosis of lowgrade adenosquamous carcinoma is based on histopathology. The recognition of this entity is an important consideration in the differential diagnosis of breast masses and carries implications for prognosis, which is more favorable than other types of breast carcinoma.
First described by Rosen and Ernsberger [1] in 1987, lowgrade adenosquamous carcinoma of the breast (LGAS) is a type of invasive mammary carcinoma. It is a histopathologic subtype of metaplastic carcinoma of the breast (MCB), a rare and heterogeneous group of neoplasms that constitute <5% of all breast carcinomas [2, 3] . The clinical presentation of LGAS is most commonly a painless, palpable mass, with an age distribution similar to other breast carcinomas [1,4e8] . Its mammographic and sonographic appearance is nonspecific and shares features of both benign and malignant neoplasms, including fibroadenoma and invasive ductal and invasive lobular carcinoma. As a result of these shared clinical, demographic, and imaging features, LGAS tends to be managed similar to invasive carcinoma.
Imaging Features of LGAS
The radiology literature mainly focuses on the general class of metaplastic breast carcinoma; imaging descriptions of LGAS are rare and limited to case reports and small series [4, 5, 7] . Available descriptions of LGAS suggest nonspecific imaging findings with no pathognomonic features. Mammographic features include solid masses with a nodular or stellate appearance [4, 5] . Margins may be spiculated or poorly defined [4, 5] . Microcalcifications have been reported but are uncommon [1, 4, 5, 8] . Sonographic features may include a solid, irregular hypoechoic mass with ill-defined borders [4, 7] .
Histologic Features of LGAS
On histologic examination, LGAS exhibits both glandular and squamous differentiation, and exhibits immunoexpression of myoepithelial markers [1, 7, 9] . It features a stellate or infiltrating configuration with poorly defined margins compared with the firm, nodular, and well-circumscribed appearance generally found in high-grade MCBs. By definition, LGAS is classified as a low-or intermediate-grade tumour when using the Nottingham grading system.
LGAS may be difficult to diagnose on histologic examination, because its appearance mimics benign or other low- grade lesions [1, 4] . It features an infiltrative pattern, with small round-to-irregular tubular glands embedded in dense collagenized stroma. In addition, it exhibits low-grade cytologic atypia, few mitoses, and a lack of necrosis [1, 4] .
LGAS may be difficult to recognize on fine needle aspiration cytology, core needle biopsy, and intraoperative frozen sections. Often, an excision biopsy is required to establish a definitive diagnosis.
Clinical Features of LGAS
The clinical course and prognosis of LGAS differs from the broader category of MCB. Clinically, most MCB are characterized by aggressive behavior, with a high rate of metastases at diagnosis, chemoresistance, and poorer clinical outcome than other breast malignancies [10e13]. By contrast, LGAS has a more favorable prognosis and tends towards an indolent clinical course. Although risk for local recurrence has led to aggressive local treatment (eg, wide local excision or mastectomy) to achieve clear margins, there is a very low incidence of axillary lymph node involvement and metastatic disease [7, 9, 14] . Overall, LGAS are considered to be low-grade tumours with an excellent prognosis.
Study Design
A retrospective review was conducted of patients referred to the British Columbia Cancer Agency who were diagnosed with LGAS between 1989 and 2010. Twenty-two cases were found, 10 of which had the imaging available, which made these patients eligible for inclusion in our study. Mammographic (n ¼ 8) and sonographic (n ¼ 7) findings were analysed together with pathologic findings, with follow-up over 2-11.5 years. 
Summary of Findings
The patient age range was 30-81 years, with a mean age of 64.8 years. The presenting symptom was a palpable abnormality in 5 patients, nonpalpable mass identified by screening mammography in 1 patient, and suspicious calcifications identified by screening mammography in 2 patients. Nipple changes, including nipple retraction in 1 patient and nipple hardening in 1 patient, were also presenting symptoms. The size of lesions on screening mammography ranged from 0.7-3.0 cm, with an average size of 1.8 cm. Calcifications were detected in 2 patients. Mammographic findings were varied: ill-defined asymmetry ( Figure 1A, B ), malignant-type calcifications (Figure 2) , a well-defined mass with calcifications ( Figure 3) , and a spiculated mass (Figures 4 to 6A) were observed. Sonographic findings included acoustic shadowing ( Figure 6B ) and hypoechoic lesions with sharply-defined ( Figure 7 ) and poorly defined borders (Figure 8 ) as well as internal cystic areas ( Figure 9A) . The mammographic and sonographic features of the patients included in the study are summarized in Table 1 .
On pathologic examination, LGAS specimens demonstrated scattered benign-looking glandular and squamous components, which were often challenging to recognize due to their similar appearance to normal mammary glands ( Figure 9B, C) . Microscopic calcifications were largely absent, seen only in a minority of cases. There were no in situ components. There were no metastasis to axillary lymph nodes or systemic metastases. In all cases, tumour makers were triple negative for the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu).
Treatment and Follow-up
The management of low-grade adenosquamous carcinoma varied among patients. In terms of surgical management, 3 patients underwent mastectomies and 7 patients underwent breast-conserving surgery. Seven of the patients had axillary node dissection performed, none of which showed positive nodes. Seven of the patients had radiation therapy. One patient had chemotherapy. The follow-up of the patients in this study ranged from 2-11.5 years, with an average of 6.5 years. Consistent with the majority of cases in the published literature, there were no cases of distant metastases after definitive therapy. Retrospectively, however, 1 patient was diagnosed with local recurrence. Six years before her diagnosis of LGAS, she detected a mass that was surgically removed and originally called benign. She presented again with a mass in the same area, and the pathology from her previous mass was reviewed and the diagnosis of LGAS was made.
Conclusion
In this study, LGAS was found to present as a solid mass with a variety of mammographic and sonographic findings, and no unique imaging features. Lesions were most commonly periareolar in location and with few associated calcifications. None of the patients had a positive axillary dissection, and all of the tumours were hormone receptor negative. Only one of the tumours in our study recurred, and none metastasized. These findings are consistent with the published literature.
The imaging appearance of LGAS in this study overlaps with other benign and malignant neoplasms, including fibroadenoma and invasive ductal and invasive lobular carcinomas. As a result, LGAS cannot be diagnosed with confidence based on imaging alone; biopsy with pathologic diagnosis is essential to definitive establish the tumour type.
The findings in this group of patients with pathologyproven LGAS underscore the indolent clinical course observed in the published literature. In light of the absence of lymph-node involvement and systemic metastasis, this begs the question as to whether patients have been overtreated in the past. Although the role of wide local excision is well established, the use of adjuvant treatment such as chemotherapy and radiation are of questionable benefit. 
